MX2019011925A - Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. - Google Patents

Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Info

Publication number
MX2019011925A
MX2019011925A MX2019011925A MX2019011925A MX2019011925A MX 2019011925 A MX2019011925 A MX 2019011925A MX 2019011925 A MX2019011925 A MX 2019011925A MX 2019011925 A MX2019011925 A MX 2019011925A MX 2019011925 A MX2019011925 A MX 2019011925A
Authority
MX
Mexico
Prior art keywords
derivatives
ocular hypertension
treating glaucoma
prostaglandin
conjugates
Prior art date
Application number
MX2019011925A
Other languages
English (en)
Other versions
MX381356B (es
Inventor
Ellis David
Scheibler Lukas
Sharif Najam
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019011925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019011925A publication Critical patent/MX2019011925A/es
Publication of MX381356B publication Critical patent/MX381356B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/02—Preparation of esters of nitric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C203/00—Esters of nitric or nitrous acid
    • C07C203/02—Esters of nitric acid
    • C07C203/08—Esters of nitric acid having nitrate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/08—Azoxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer conjugados y derivados de prostaglandina y los métodos para su uso para tratar el glaucoma y/o presión inferior intraocular. Adicionalmente, las composiciones farmacéuticas oftálmicas útiles en el tratamiento de enfermedades oculares tales como el glaucoma y la presión intraocular elevada se dan a conocer. Tales composiciones comprenden una cantidad eficaz de conjugados o derivados de prostaglandina de la presente invención.
MX2019011925A 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. MX381356B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064193P 2014-10-15 2014-10-15
PCT/US2015/055766 WO2016061370A1 (en) 2014-10-15 2015-10-15 Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension

Publications (2)

Publication Number Publication Date
MX2019011925A true MX2019011925A (es) 2019-11-18
MX381356B MX381356B (es) 2025-03-12

Family

ID=54478216

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2020012011A MX391657B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
MX2019011925A MX381356B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2020012012A MX391658B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
MX2020012014A MX391659B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
MX2017004809A MX375963B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020012011A MX391657B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2020012012A MX391658B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
MX2020012014A MX391659B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
MX2017004809A MX375963B (es) 2014-10-15 2015-10-15 Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.

Country Status (12)

Country Link
US (2) US9604949B2 (es)
EP (1) EP3206693B1 (es)
JP (2) JP6654757B2 (es)
KR (1) KR20170066427A (es)
CN (2) CN112022856A (es)
AR (1) AR102283A1 (es)
AU (1) AU2015332447B2 (es)
BR (1) BR112017007095B1 (es)
CA (1) CA2964364A1 (es)
MX (5) MX391657B (es)
RU (1) RU2712221C2 (es)
WO (1) WO2016061370A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
KR102282716B1 (ko) * 2020-02-07 2021-07-29 포항공과대학교 산학협력단 일산화질소 공여체를 포함하는 뇌-혈관 장벽 투과성을 증가시키는데 사용하기 위한 조성물 및 그의 용도
JP2023524494A (ja) 2020-05-01 2023-06-12 リップル セラピューティクス コーポレーション 眼障害を処置するためのヘテロ二量体組成物と方法
CN118084895B (zh) * 2024-02-28 2025-09-05 中国药科大学 一种一氧化氮供体型Omidenepag衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4057189A (en) * 1988-08-23 1990-03-23 Aktiebolaget Hassle Treatment of glaucoma and related disorders in the human eye with pyridinylmethyl (sulfinyl or thio)benzimidazoles
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6417228B1 (en) * 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
OA13356A (en) * 2004-01-05 2007-04-13 Nicox Sa Prostaglandin nitrooxyderivatives.
WO2007000641A2 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Prostaglandin derivatives
WO2007044963A2 (en) * 2005-10-13 2007-04-19 Novokin Biotech Inc. Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions
CA2721749A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
US20120209011A1 (en) * 2009-11-05 2012-08-16 Chandrashekar Aswathanarayanappa novel process for the preparation of prostaglandins and intermediates thereof
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US9248135B2 (en) 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use

Also Published As

Publication number Publication date
MX2020012014A (es) 2022-04-19
WO2016061370A1 (en) 2016-04-21
AU2015332447A1 (en) 2017-04-27
JP2020023556A (ja) 2020-02-13
MX375963B (es) 2025-03-07
KR20170066427A (ko) 2017-06-14
BR112017007095B1 (pt) 2023-03-14
US9604949B2 (en) 2017-03-28
MX2017004809A (es) 2017-07-26
MX381356B (es) 2025-03-12
BR112017007095A2 (pt) 2017-12-26
US20170239268A1 (en) 2017-08-24
RU2712221C2 (ru) 2020-01-27
AU2015332447B2 (en) 2018-10-25
MX2020012012A (es) 2022-04-19
JP6830991B2 (ja) 2021-02-17
MX391657B (es) 2025-03-21
CN112022856A (zh) 2020-12-04
AR102283A1 (es) 2017-02-15
EP3206693A1 (en) 2017-08-23
JP6654757B2 (ja) 2020-02-26
CN107106573A (zh) 2017-08-29
EP3206693B1 (en) 2022-08-03
RU2017116230A3 (es) 2019-05-22
MX391658B (es) 2025-03-21
MX2020012011A (es) 2022-04-19
US20160108012A1 (en) 2016-04-21
US10016441B2 (en) 2018-07-10
RU2017116230A (ru) 2018-11-15
CA2964364A1 (en) 2016-04-21
MX391659B (es) 2025-03-21
JP2017531018A (ja) 2017-10-19

Similar Documents

Publication Publication Date Title
CL2016000060A1 (es) Derivados piperidinil indol y su uso como inhibidores factor de complemento b.
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
MX2018003542A (es) Metodos para tratar presion intraocular con activadores de tie-2.
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
EA201790889A1 (ru) Офтальмологический раствор
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX372988B (es) Composiciones oftalmicas estabilizadas de omega 3.
CO2017005404A2 (es) Anticuerpos contra il-6
MX2016014854A (es) Compuestos y composiciones para inducir condrogenesis.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112016017817A2 (pt) composições e métodos para o tratamento e a prevenção de degeneração macular
EP4420726A3 (en) Fixed dose combination of bromonidine and timolol
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
MX2017005064A (es) Metodos para tratar afecciones oculares.
IT201600103956A1 (it) Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
BR112014020424A2 (pt) ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
CR20170346A (es) Composiciones para el tratamiento de infecciones producidas por el ácaro demodex spp
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
PT3810758T (pt) Métodos e composições para produzir células do epitélio do pigmento da retina
CO2017002963A2 (es) Espiro-tiazolonas